Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200 Day Moving Average of $11.18

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $11.18 and traded as high as $13.05. Assembly Biosciences shares last traded at $12.95, with a volume of 13,958 shares traded.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ASMB shares. StockNews.com raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a report on Monday, April 1st.

Assembly Biosciences Stock Performance

The business’s 50-day moving average is $13.26 and its 200-day moving average is $11.18. The company has a market capitalization of $71.00 million, a PE ratio of -0.76 and a beta of 0.60.

Hedge Funds Weigh In On Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned about 0.08% of Assembly Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.